
Zymeworks Inc (ZYME) Stock Forecast & Price Target
Zymeworks Inc (ZYME) Analyst Ratings
Bulls say
Zymeworks Inc has demonstrated promising clinical trial results, particularly with Ziihera in combination with chemotherapy, which revealed statistically significant improvements in progression-free survival and overall survival compared to the control arm, enhancing the drug's approval probability to 90%. In the third quarter of 2025, the company reported a narrower net loss of $0.26 per share, indicating better-than-expected financial performance compared to prior forecasts. Additionally, adjustments to the discounted cash flow (DCF) valuation method, including a lowered discount rate, suggest a more favorable financial outlook and an increase in projected stock valuation.
Bears say
Zymeworks Inc faces significant challenges that contribute to a negative financial outlook, including its inability to scale up manufacturing for biparatopic antibodies and secure timely European approval for zanidatamab. Additionally, the company is grappling with risks associated with partnerships, as well as poorer-than-expected commercial uptake of its products, which could exacerbate projected net losses, estimated at $1.75 per share for full-year 2025. There are also concerns regarding potential clinical trial failures due to safety and efficacy issues, alongside long-term dilution risks that may jeopardize shareholder value.
This aggregate rating is based on analysts' research of Zymeworks Inc and is not a guaranteed prediction by Public.com or investment advice.
Zymeworks Inc (ZYME) Analyst Forecast & Price Prediction
Start investing in Zymeworks Inc (ZYME)
Order type
Buy in
Order amount
Est. shares
0 shares